FDA Approves Fabre-Kramer Pharmaceuticals Major Depressive Disorder Treatment
EXXUA has been approved for treatment.
Fabre-Kramer Pharmaceuticals announced that the FDA has approved its treatment of major depressive disorder in adults.
In a press release, the company wrote that Exxua is the first antidepressant to be approved with a novel mechanism of action and is able to selectively target the serotonin 1A receptor.
"Exxua represents an important milestone in the treatment of MDD, a serious and debilitating condition that affects millions of people worldwide," said Stephen Kramer, M.D., CEO of Fabre-Kramer in a press release. "There is value in providing prescribers and patients with a wide range of effective options for use in clinical practice. We are proud to bring this innovative therapy to patients who need a new option to manage their depression and improve their quality of life."
According to Fabre-Kramer, Exxua is expected to be available in pharmacies starting in early 2024.
Source
(Sept. 28, 2023); Fabre-Kramer Pharmaceuticals; Fabre-Kramer Pharmaceuticals Announces FDA Approval of EXXUA™, the First and Only Oral Selective 5HT1a Receptor Agonist for the Treatment of Major Depressive Disorder in Adults; https://www.prnewswire.com/news-releases/fabre-kramer-pharmaceuticals-announces-fda-approval-of-exxua-the-first-and-only-oral-selective-5ht1a-receptor-agonist-for-the-treatment-of-major-depressive-disorder-in-adults-301941467.html
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Social Media's Influence on Young Women's Reproductive Decisions
February 20th 2025In this Q&A, Organon's Chief Communications Officer, Becky Edwards discusses how much social media and influencers sway decisions about birth control methods, potential consequences of these misinformed choices, and more.
